ArticleBMC pharmacology & toxicology2019

Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada.

Maria Luisa Aznar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.